Home > Insider Trading > Filing (0001104659-11-018941)

Filing Details

Accession Number:: 0001104659-11-018941
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-04-06 17:11:36
Reporting Period:: 2011-04-06

Filing Date:: 2011-04-06
Accepted Time:: 2011-04-06 17:11:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274644	Tranzyme Inc	TZYM	Pharmaceutical Preparations (2834)	631192270

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1430885	Bdc Capital Inc.	5 Place Ville Marie, Suite 300 Montreal, Quebec, Canada H3B 5E7		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-04-06	307,287	$0.00	307,287	No	4	C	Direct
Common Stock	Acquisiton	2011-04-06	16,108	$0.00	323,395	No	4	C	Direct
Common Stock	Acquisiton	2011-04-06	915,430	$0.00	1,238,825	No	4	C	Direct
Common Stock	Acquisiton	2011-04-06	1,000,000	$4.00	2,238,825	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2011-04-06	2,151,014	$0.00	307,287	$0.00
Common Stock	Common Exchangeable Shares of Tranzyme Pharma Inc.	Disposition	2011-04-06	112,758	$0.00	16,108	$0.00
Common Exchangeable Shares Of Tranzyme Pharma	Preferred Exchangeable Shares of Tranzyme Pharma Inc.	Disposition	2011-04-06	6,408,016	$0.00	915,430	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each share of the Issuer's Series A Convertible Preferred Stock automatically converted, for no additional consideration, into shares of Common Stock prior to the closing of the Issuer's initial public offering on a 7-for-1 basis, reflecting a 1-for-7 reverse stock split which became effective on March 31, 2011.
The Common Exchangeable Shares of Tranzyme Pharma Inc. were automatically exchanged for shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering on a 7-for-1 basis, reflecting a 1-for-7 reverse stock split of the Issuer's Common Stock which became effective on March 31, 2011.
The Preferred Exchangeable Shares of Tranzyme Pharma Inc. automatically converted into Common Exchangeable Shares of Tranzyme Pharma Inc. prior to the closing of the Issuer's initial public offering in a corporate reorganization.
These securities are owned of record by BDC Capital Inc. BDC Capital Inc. is a wholly owned subsidiary of Business Development Bank of Canada ("BDC"), a Crown Corporation. Voting and investment decisions are made through a sub committee of the board of directors of the BDC, the Credit/Investment and Risk Committee. The members of that committee are all directors of BDC: Thomas Spencer, Eric Boyko, Stan Bracken-Horrocks, Jean-Rene Halde, Prashant Shanker Pathak and Rosemary Zigrossi, each of whom disclaims beneficial ownership of such securities except to the extent of his or her pecuniary interest therein.
These shares were purchased in the Issuer's initial public offering.